CardieX (ASX:CDX), formerly known as AtCor Medical, says it is pleased to report "encouraging results" of a trial of the commercial application of its wave analysis (PWA) technology in a wearable blood pressure sensor.
The 8-week, 15-person trial with The Faculty of Medicine and Health Sciences at Macquarie University was part of a strategic collaboration with Blumio, a Silicon Valley-based blood pressure sensor company.
The company said as part of a multi-phase program, this first trial assessed the feasibility of obtaining cardiovascular blood pressure related data utilising Blumio’s radar frequency sensor and analysing it via CardieX PWA technology.
The trial was led by CardieX Principal Scientist, Dr Ahmad Qasem, together with Professor Alberto Avolio of Macquarie University.
"The results of this initial trial demonstrated that using CardieX technology together with Blumio’s sensor you could accurately extract cardiovascular signals from a variety of trial patient subjects with differing cardiovascular conditions as well as track changes in cardiovascular events in those patients – thereby making the sensor suitable for specific cardiovascular monitoring applications," said the company in a statement.
According to CardieX CEO, Craig Cooper, “In order to develop a commercial wearable blood pressure sensor it requires the extraction of precise cardiovascular and blood pressure data from the relevant sensor.
"This initial trial is extremely encouraging as a clear demonstration of the use of our technology to extract specific blood pressure data from a wearable sensor.
"We are continuing to refine the data obtained in the trial but our analysis to date has shown that with further neural learning - and the application of our proprietary algorithms - we have the ability to extract a wide range of commercially viable medical and consumer data from the sensor.”
